Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 21, 2026, 4:19 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 217–240 of 2,373 matching trials from the live ClinicalTrials.gov search.
Filters: Condition: Visual Function Clear all
Withdrawn Not applicable Interventional

RETINA IMPLANT Alpha AMS in Blind Patients With Retinitis Pigmentosa

NCT03629899
View directory record Official record
Conditions
Retinitis Pigmentosa
Interventions
RETINA IMPLANT Alpha AMS
Device
Lead sponsor
Wills Eye
Other
Eligibility
50 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2025
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated May 10, 2019 · Synced Oct 21, 2026, 4:19 PM EDT
Withdrawn Phase 4 Interventional

Augmented Macular Pigment-containing Nutraceutical and Central Visual Function

NCT04676126
View directory record Official record
Conditions
Glaucoma, Glaucoma Eye, Glaucoma, Open-Angle
Interventions
Lumega-Z, Dorzolamide Hcl 2% Oph Soln, Placebo
Dietary Supplement · Drug · Other
Lead sponsor
University of the Incarnate Word
Other
Eligibility
18 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2022
U.S. locations
1
States / cities
San Antonio, Texas
Source: ClinicalTrials.gov public record
Updated Oct 4, 2022 · Synced Oct 21, 2026, 4:19 PM EDT
Completed Phase 2Phase 3 Interventional

Supplemental Therapeutic Oxygen for Prethreshold Retinopathy of Prematurity

NCT01203436
View directory record Official record
Conditions
Infant, Newborn, Infant, Low Birth Weight, Infant, Small for Gestational Age, Infant, Premature, Retinopathy of Prematurity, Blindness
Interventions
Supplemental Oxygen Management, Conventional Oxygen Management
Procedure
Lead sponsor
NICHD Neonatal Research Network
Network
Eligibility
Up to 48 Hours
Enrollment
649 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
1994 – 1999
U.S. locations
9
States / cities
Palo Alto, California • New Haven, Connecticut • Atlanta, Georgia + 6 more
Source: ClinicalTrials.gov public record
Updated Jun 8, 2015 · Synced Oct 21, 2026, 4:19 PM EDT
Recruiting Early Phase 1 Interventional

Study of Biodistribution, Metabolism, Excretion and Brain Uptake 18F-JSS20-183A

NCT06932809
View directory record Official record
Conditions
Tauopathies
Interventions
18F-JSS20-183A PET, Brain MRI, Amyloid PET, Neurological Assessments
Drug · Diagnostic Test · Behavioral
Lead sponsor
University of Pennsylvania
Other
Eligibility
40 Years to 85 Years
Enrollment
90 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2030
U.S. locations
2
States / cities
San Francisco, California • Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Dec 23, 2025 · Synced Oct 21, 2026, 4:19 PM EDT
Completed Not applicable Interventional Results available

Additional Long-Term Follow-up for Subjects Implanted With a CyPass® Micro-Stent

NCT04629521
View directory record Official record
Conditions
Primary Open Angle Glaucoma, Cataract
Interventions
CyPass Micro-Stent, Cataract Surgery
Device · Procedure
Lead sponsor
Alcon Research
Industry
Eligibility
45 Years and older
Enrollment
54 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2023
U.S. locations
12
States / cities
Glendale, Arizona • Orange, California • Fort Collins, Colorado + 9 more
Source: ClinicalTrials.gov public record
Updated Apr 26, 2024 · Synced Oct 21, 2026, 4:19 PM EDT
Completed Phase 3 Interventional Results available

"Efficacy and Safety of Brimonidine Tartrate Preservative-Free Formulation in Adults With Ocular Redness"

NCT05360784
View directory record Official record
Conditions
Ocular Redness
Interventions
Brimonidine tartrate ophthalmic solution 0.025% preservative-free formulation, Lumify® (brimonidine tartrate ophthalmic solution 0.025%)
Drug
Lead sponsor
Bausch & Lomb Incorporated
Industry
Eligibility
18 Years and older
Enrollment
380 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022
U.S. locations
6
States / cities
Colorado Springs, Colorado • Louisville, Kentucky • Andover, Massachusetts + 3 more
Source: ClinicalTrials.gov public record
Updated Aug 26, 2024 · Synced Oct 21, 2026, 4:19 PM EDT
Completed Phase 1 Interventional

28-Day Repeated Topical Study to Evaluate the Safety and Activity of 5 Escalating Dose Levels of SAR366234 and One Dose of Latanoprost in Patients With Open Angle Glaucoma or Ocular Hypertension

NCT02531152
View directory record Official record
Conditions
Open Angle Glaucoma -Ocular Hypertension
Interventions
Latanoprost, SAR366234
Drug
Lead sponsor
Sanofi
Industry
Eligibility
18 Years and older
Enrollment
54 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2016
U.S. locations
5
States / cities
Inglewood, California • Cape Coral, Florida • Roswell, Georgia + 2 more
Source: ClinicalTrials.gov public record
Updated Apr 27, 2016 · Synced Oct 21, 2026, 4:19 PM EDT
Recruiting Not applicable Interventional

Nanodropper Use in Primary Open-Angle Glaucoma Patients: A Non-Inferiority Trial

NCT05844384
View directory record Official record
Conditions
Ocular Hypertension, Primary Open Angle Glaucoma
Interventions
Nanodropper, Regular dropper
Device
Lead sponsor
59th Medical Wing
Federal
Eligibility
18 Years and older
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2024
U.S. locations
1
States / cities
Lackland Air Force Base, Texas
Source: ClinicalTrials.gov public record
Updated May 6, 2023 · Synced Oct 21, 2026, 4:19 PM EDT
Completed Phase 2Phase 3 Interventional Accepts healthy volunteers

Aqueous Humor Dynamics of NCX 470 Ophthalmic Solution

NCT05938699
View directory record Official record
Conditions
Open Angle Glaucoma
Interventions
NCX 470, Placebo
Drug
Lead sponsor
Nicox Ophthalmics, Inc.
Industry
Eligibility
18 Years and older
Enrollment
18 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2023 – 2025
U.S. locations
1
States / cities
Rochester, Minnesota
Source: ClinicalTrials.gov public record
Updated Sep 8, 2025 · Synced Oct 21, 2026, 4:19 PM EDT
Withdrawn No phase listed Observational

The Effect of Omega-3 Fatty Acid Supplementation on Intraocular Pressure & Ocular Surface

NCT02295358
View directory record Official record
Conditions
Open Angle Glaucoma, Ocular Hypertension
Interventions
Not listed
Lead sponsor
University of Colorado, Denver
Other
Eligibility
40 Years to 89 Years
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2015
U.S. locations
1
States / cities
Aurora, Colorado
Source: ClinicalTrials.gov public record
Updated Jul 9, 2015 · Synced Oct 21, 2026, 4:19 PM EDT
Completed No phase listed Observational

Human CNS Tau Kinetics in Tauopathies

NCT03545126
View directory record Official record
Conditions
Progressive Supranuclear Palsy (PSP), Corticobasal Degeneration (CBD), Frontotemporal Dementia (FTD MAPT Mutation)
Interventions
13C6 Leucine
Other
Lead sponsor
Washington University School of Medicine
Other
Eligibility
18 Years and older
Enrollment
27 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2022
U.S. locations
1
States / cities
St Louis, Missouri
Source: ClinicalTrials.gov public record
Updated Apr 13, 2022 · Synced Oct 21, 2026, 4:19 PM EDT
Completed Phase 1Phase 2 Interventional Results available

H-1337 Ophthalmic Solution Phase 1/2

NCT03452033
View directory record Official record
Conditions
Glaucoma, Open-Angle
Interventions
H-1337 Placebo, H-1337 [1], H-1337 [2], H-1337 [3]
Drug
Lead sponsor
Allysta Pharmaceutical
Industry
Eligibility
18 Years to 99 Years
Enrollment
87 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018
U.S. locations
1
States / cities
Goose Creek, South Carolina
Source: ClinicalTrials.gov public record
Updated Jul 12, 2022 · Synced Oct 21, 2026, 4:19 PM EDT
Completed No phase listed Observational Accepts healthy volunteers

Macular Damage in Early Glaucoma and Progression

NCT02547740
View directory record Official record
Conditions
Glaucoma
Interventions
Not listed
Lead sponsor
Columbia University
Other
Eligibility
18 Years to 85 Years
Enrollment
260 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2015 – 2024
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated May 14, 2024 · Synced Oct 21, 2026, 4:19 PM EDT
Completed Not applicable Interventional Results available

inVENT-visIOn Study

NCT01444391
View directory record Official record
Conditions
Otitis Media
Interventions
Tympanostomy tube placement (Acclarent iontophoresis device)
Device
Lead sponsor
Integra LifeSciences Corporation
Industry
Eligibility
6 Months and older
Enrollment
42 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2012
U.S. locations
1
States / cities
Port Saint Lucie, Florida
Source: ClinicalTrials.gov public record
Updated Jul 12, 2024 · Synced Oct 21, 2026, 4:19 PM EDT
Completed Not applicable Interventional

A Comparison of Two Ab Interno Procedures in the Treatment of Glaucoma in Patients Undergoing Cataract Extraction

NCT02784249
View directory record Official record
Conditions
Open Angle Glaucoma
Interventions
Goniotomy, Trabecular Micro-Bypass Stent, Cataract Extraction
Procedure · Device
Lead sponsor
New World Medical, Inc.
Industry
Eligibility
18 Years to 90 Years
Enrollment
166 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2018
U.S. locations
1
States / cities
La Crosse, Wisconsin
Source: ClinicalTrials.gov public record
Updated Jul 14, 2021 · Synced Oct 21, 2026, 4:19 PM EDT
Withdrawn Not applicable Interventional Accepts healthy volunteers

OCT Image Quality Performance Evaluation

NCT02991027
View directory record Official record
Conditions
Healthy Eyes
Interventions
DRI OCT Triton
Device
Lead sponsor
Topcon Medical Systems, Inc.
Industry
Eligibility
18 Years and older
Healthy volunteers
Accepts healthy volunteers
Timeline
2016 – 2017
U.S. locations
1
States / cities
Oakland, New Jersey
Source: ClinicalTrials.gov public record
Updated Dec 16, 2021 · Synced Oct 21, 2026, 4:19 PM EDT
Completed Phase 3 Interventional

Occlusion Versus Pharmacologic Therapy for Moderate Amblyopia

NCT00000170
View directory record Official record
Conditions
Amblyopia
Interventions
Atropine, Eye Patch
Drug · Device
Lead sponsor
Jaeb Center for Health Research
Other
Eligibility
Up to 6 Years
Enrollment
419 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
1999 – 2013
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Mar 6, 2014 · Synced Oct 21, 2026, 4:19 PM EDT
Terminated Phase 4 Interventional

A Clinical Trial Comparing the OMNI Surgical System to Standard Medical Treatment in Patients With Primary Open Angle Glaucoma

NCT06407973
View directory record Official record
Conditions
Primary Open Angle Glaucoma
Interventions
OMNI Surgical System, Latanoprost plus adjunctive glaucoma medication
Device · Drug
Lead sponsor
Sight Sciences, Inc.
Industry
Eligibility
45 Years and older
Enrollment
2 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2025
U.S. locations
2
States / cities
Petaluma, California • Maryville, Tennessee
Source: ClinicalTrials.gov public record
Updated Jan 29, 2025 · Synced Oct 21, 2026, 4:19 PM EDT
Completed No phase listed Observational Accepts healthy volunteers

Slit Lamp and Digital Camera Attachment

NCT02444039
View directory record Official record
Conditions
Any Willing and Able Person for Ocular Imaging
Interventions
SL-D301, DC-4, SL-3G
Device
Lead sponsor
Topcon Medical Systems, Inc.
Industry
Eligibility
18 Years and older
Enrollment
20 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2014
U.S. locations
1
States / cities
Oakland, New Jersey
Source: ClinicalTrials.gov public record
Updated Jun 8, 2022 · Synced Oct 21, 2026, 4:19 PM EDT
Completed Not applicable Interventional Accepts healthy volunteers Results available

Evaluation of Vision After Vivity IOL Implantation With a Target of Slight Myopia in the Non-dominant Eye

NCT04482439
View directory record Official record
Conditions
Cataract
Interventions
Vivity Extended Depth of Focus intraocular lens (IOL)
Device
Lead sponsor
Newsom Eye & Laser Center
Other
Eligibility
40 Years and older
Enrollment
35 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2020 – 2021
U.S. locations
1
States / cities
Sebring, Florida
Source: ClinicalTrials.gov public record
Updated Mar 3, 2022 · Synced Oct 21, 2026, 4:19 PM EDT
Recruiting Phase 1Phase 2 Interventional

A Study to Investigate the Safety and Efficacy of IOV-3001 in Adults With Advanced Melanoma Who Will Receive Lifileucel

NCT06940739
View directory record Official record
Conditions
Unresectable Melanoma, Metastatic Melanoma, Ocular Melanoma
Interventions
IOV-3001
Biological
Lead sponsor
Iovance Biotherapeutics, Inc.
Industry
Eligibility
18 Years to 70 Years
Enrollment
42 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2032
U.S. locations
3
States / cities
Denver, Colorado • Chapel Hill, North Carolina • Nashville, Tennessee
Source: ClinicalTrials.gov public record
Updated Jun 15, 2026 · Synced Oct 21, 2026, 4:19 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Pilot Clinical Evaluation of Approved Contact Lenses

NCT02540122
View directory record Official record
Conditions
Vision Disorders
Interventions
Marketed Contact Lens 1, Marketed Contact Lens 2, Marketed Contact Lens 3, Marketed Contact Lens 4
Device
Lead sponsor
Johnson & Johnson Vision Care, Inc.
Industry
Eligibility
18 Years to 70 Years
Enrollment
30 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2015 – 2016
U.S. locations
1
States / cities
Miami, Florida
Source: ClinicalTrials.gov public record
Updated Jun 20, 2017 · Synced Oct 21, 2026, 4:19 PM EDT
Recruiting Phase 3 Interventional

A Study to See if Lepodisiran Can Reduce Plaque in Coronary Arteries of Adults With Elevated Lp(a) Who Have Had Heart Events or Are at High Risk

NCT07613294
View directory record Official record
Conditions
Atherosclerosis, Cardiovascular Diseases, Lipoprotein(a)
Interventions
Lepodisiran, Placebo
Drug
Lead sponsor
Eli Lilly and Company
Industry
Eligibility
45 Years to 80 Years
Enrollment
252 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2029
U.S. locations
17
States / cities
La Jolla, California • Northridge, California • Torrance, California + 14 more
Source: ClinicalTrials.gov public record
Updated Oct 8, 2026 · Synced Oct 21, 2026, 4:19 PM EDT
Enrolling by invitation No phase listed Observational Accepts healthy volunteers

Use of Apple Vision Pro as Virtual Monitor for Diagnostic and Therapeutic Procedures

NCT07797556
View directory record Official record
Conditions
Device Convenience, Device Performance, Surgeons' Rating, Ergonomics
Interventions
Not listed
Lead sponsor
The Methodist Hospital Research Institute
Other
Eligibility
18 Years and older
Enrollment
4 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2025 – 2027
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Sep 1, 2026 · Synced Oct 21, 2026, 4:19 PM EDT